Navigation Links
Rhode Island Biotechnology Company Develops Tularemia Vaccine

EpiVax, Inc, a leader in genome-derived vaccines, announced today that it has developed a promising tularemia vaccine // candidate (TuliVaxTM) that confers protective immunity. Francisella tularensis is a bacterium considered to be one of the most dangerous potential bioterror agents.

This vaccine project was funded by a BioDefense Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). The animal studies, conducted at Rhode Island Hospital, showed that TuliVaxTM protected mice from lethal bacterial challenge.

“Our unique ability to develop safe and effective vaccines by screening whole genomes for candidate vaccine components with computer algorithms is at the core of this research effort,” said Anne De Groot, M.D., President and CEO of EpiVax. “These study results highlight the ability of our computer-aided vaccine design (VaccineCAD) approach to create effective and innovative vaccines at an accelerated pace”.

Tularemia is rare but does occur naturally; the most lethal pulmonary form is more common in Martha’s Vineyard than in most other places in the world. EpiVax collaborated with Martha’s Vineyard Hospital to obtain bloods from people with previous tularemia infection; 95% of the study participants demonstrated robust responses to the TuliVaxTM components.

Mice with “humanized” immune systems were used by Rhode Island Hospital collaborator Stephen Gregory PhD, Associate Professor of Medicine, Department of Medicine, Rhode Island Hospital and Brown Medical School, to assess the ability of the vaccine to protect against a lethal dose of F. tularensis. Although all of the mice that received a placebo vaccine died when exposed to tularemia, the majority of the mice that received TuliVaxTM survived.

The development of a safe and effective tularemia vaccine has proven elusive; the live vaccine str ain (LVS) of tularensis was the major tularemia vaccine under study for many years. Although it conferred partial protection, federal funding to license LVS has been cancelled due to safety and manufacturing concerns1.

“There is an urgent need for a safe, effective tularemia vaccine to address both natural infections and potential biothreats. TuliVax is likely to be safe because it is composed of small synthetic parts, not the live bacterium”, says Dr. Gregory. “Preliminary results in mice are encouraging; additional experiments are required to provide the data needed for TuliVax to progress to human clinical trials.”



Source-Bio-Bio Technoogy
SRI
'"/>




Related medicine news :

1. Rhode Island legalizes use and possession of Marijuana
2. Meningitis Scare Keeps Children At Home In Rhode Island
3. Rhode Island legalizes use and possession of Marijuana
4. Chikungunya Epidemic On French Island Claims 52 lives
5. French Minister To Visit La Reunion Island To Monitor Chikungunya Epidemic
6. Phoenix Islands To Be Protected Under Global Conservation Map
7. Assams Floating Hospital To Render Medical Services To Islanders
8. Reports Of A HIV Break Out Scare People Of A Holiday Island
9. King Island Water Certified Potable
10. E. coli causes havoc in Fire Island
11. Meningitis Scare Keeps Children At Home In Rhode Island
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, single-family ... some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average ... extremely low property-tax rates, which contributes to the relatively lower cost of living ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm ... California Berkeley, and other leading institutions in announcing the launch of the ... change the way animals are raised for food. , Founding members of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Nvision Biomedical ... staff with the addition of industry sales leader, Thomas (Tom) Slott, as Senior ... national distribution and sales network, direct the efforts of the surgical sales teams, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017 Halo Labs announces the European launch of their ... HORIZON at MIBio 2017 in Cambridge, U.K ... matter in biopharmaceutical samples with unprecedented speed and sensitivity while using ... Backgrounded Membrane Imaging. ... subvisible particle analysis system ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
Breaking Medicine Technology: